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Simple Summary: Tumors with homologous recombination deficiency (HRD) respond to Poly-ADP
ribose polymerase inhibitor (PARPi) therapy in breast, ovarian, prostate, and pancreatic cancers.
However, in addition to a handful of known pathogenic variants including those affecting BRCA1/2,
it remains unclear what other genomic events can cause HRD. Our study systematically examined the
germline and somatic genome of over 9000 cancers. We identified alterations associated with HRD,
including mutations in ATM and ATR genes; specific deletions in stomach, bladder, and lung cancer;
and BRCA-wild type breast, ovarian, and pancreatic cancers. These findings suggest a potentially
broader utility for PARPi for cancers harboring a wide range of genomic alterations.
Abstract: Germline BRCA1/2 mutations associated with HRD are clinical biomarkers for sensitivity to
poly-ADP ribose polymerase inhibitors (PARPi) treatment in breast, ovarian, pancreatic, and prostate
cancers. However, it remains unclear whether other mutations may also lead to HRD and PARPi
sensitivity across a broader range of cancer types. Our goal was to determine the germline or somatic
alterations associated with the HRD phenotype that might therefore confer PARPi sensitivity. Using
germline and somatic genomic data from over 9000 tumors representing 32 cancer types, we examined
associations between HRD scores and pathogenic germline variants, somatic driver mutations, and
copy number deletions in 30 candidate genes involved in homologous recombination. We identified
several germline and somatic mutations (e.g., BRCA1/2, PALB2, ATM, and ATR mutations) associated
with HRD phenotype in ovarian, breast, pancreatic, stomach, bladder, and lung cancer. The co-
occurrence of germline BRCA1 variants and somatic TP53 mutations was significantly associated
with increasing HRD in breast cancer. Notably, we also identified multiple somatic copy number
deletions associated with HRD. Our study suggests that multiple cancer types include tumor subsets
that show HRD phenotype and should be considered in the future clinical studies of PARPi and
synthetic lethality strategies exploiting HRD, which can be caused by a large number of genomic
alterations.
Keywords: DNA damage repair; homologous recombination; germline and somatic; copy num-
ber variation
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1. Introduction
Tumor cells with homologous recombination deficiency (HRD) are vulnerable to the
inhibition of the DNA damage repair mechanism mediated by poly-ADP ribose polymerase
(PARP). PARP inhibitors (PARPi) leverage this synthetic lethality and are US FDA approved
to treat germline BRCA1 or BRCA2-mutant breast, ovarian, pancreatic, and prostate can-
cers [1–5]. Clinical trials have also demonstrated that somatic BRCA1/2 and germline PALB2
mutations, as well as HRD determined by the myChoice® CDx HRD assay (Myriad Genet-
ics Inc., Salt Lake, UT, USA) can serve as biomarkers of PARPi response [2,6,7]. Notably,
pre-clinical studies that investigated PARPi sensitivity showed a broader range of activity
than its current clinical use across cancer types including gastrointestinal and genitourinary
cancers [8–10]. These observations suggest that genomic alterations in genes involved
in homologous recombination (HR) other than BRCA1/2 could also cause HRD [2,7] and
implicate new treatment opportunities.
Many genes are involved in the homologous recombination (e.g., BRCA1/2, PALB2)
and DNA damage sensing (e.g., ATM, ATR, CHEK2) and therefore regulate HR, which
we refer to as “HR genes” herein. The function of HR genes can be disrupted through
inherited germline variants, acquired somatic mutations, epigenetic silencing, and somatic
copy number variations. Approximately 5% of all cancers represented in The Cancer
Genome Atlas (TCGA) carry germline pathogenic variants in HR genes [11,12], and cancers
also frequently harbor somatic mutations or show copy-number deletions [13]. These
genetic alterations are expected to disrupt DNA repair function. However, their relative
contribution to shaping HRD and their potential as biomarkers for PARPi sensitivity remain
to be determined.
Here, we systematically determined the associations between HRD phenotypes and
pathogenic germline variants, somatic driver mutations, and somatic copy number dele-
tions of 30 HR genes across 32 cancer types. Using the HRD phenotype score captured by
whole-exome sequencing and SNP array data from over 9000 cases in TCGA cohort, we
identified cancer type specific associations between germline and somatic mutations in
each HR gene with the HRD phenotype. We further utilized a structural equation modeling
method to estimate the combined germline or somatic contributions and described how
germline variants may collaborate with specific somatic drivers. We also identified novel
somatic copy number deletions that are associated with the HRD phenotype. Altogether,
these findings provide a catalog of genomic alterations that may lead to the HRD phenotype
and serve potential biomarkers for PARPi treatment.
2. Materials and Methods
2.1. Patients
We obtained germline variants and somatic mutations from 10,389 and 10,295 cases,
respectively including 10,080 samples with both types of data. We excluded the 342 hypermu-
tators and 226 microsatellite instability (MSI) high tumors from the 10,080 cases, resulting in
9512 cases that were included in our mutation analyses (Figure S1 and Table S1).
We collected gene-level and arm-level copy number variation (CNV) events from
10,713 and 10,399 cases, including 10,149 samples with both types of date. We excluded 561
cases without HRD score and 252 cases without somatic mutation data from 10,149 cases,
resulting in 9336 cases included our CNV analyses (Figure S1 and Table S1).
2.2. Genomic Datasets of TCGA Patients
TCGA HRD score: We obtained the pre-calculated HRD scores from Knijnenburg
et al. [13]. The HRD score is constructed from three types of CNV [13]: (i) binary deep
deletions from PanCanAtlas GISTIC2.0 analysis corresponding to GISTIC calls of “−2”
which indicate loss of more than half of baseline ploidy [14]; (ii) CNV burden scores
generated by TCGA PanCanAtlas Aneuploidy study using ABSOLUTE and SNP-array
data [15]; and (iii) segment loss-of-heterozygosity (LOH) scores that capture the total
number of segments with LOH [15,16]. The Knijnenburg et al. HRD score is calculated as
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the sum of the number of loss-of-heterozygosity in the genomic region of BRCA1/2 [15,16],
telomeric allelic imbalance [17], and large-scale state transitions across the entire genome
region [18]. The resulting HRD score is conceptually similar to the clinically available
MyChoice DCx assay.
TCGA germline cancer predisposing variants: we obtained 853 germlines pathogenic/
likely pathogenic variants that were identified from 10,389 patients. Germline variants were
downloaded from The Genomic Data Commons database (GDC, https://gdc.cancer.gov/
about-data/publications/PanCanAtlas-Germline-AWG (accessed on 11 August 2021)) [12,19].
TCGA somatic mutations: all somatic mutations of 10,295 cancers were obtained from
the Multi-Center Mutation Calling in Multiple Cancers (MC3) dataset [20]. Tumor mutation
burden (TMB) was calculated as the total number of all somatic mutations in all human
genes. The pre-calculated functional prediction results of all somatic mutations and the
designation of “likely driver mutation” for 299 genes were taken from TCGA PanCanAtlas
Driver study which used [21]. The likely somatic driver mutations included truncating
mutations, frameshift and in-frame shift indels, nonsense, splice site, and translation start
site mutations, or missense mutations predicted as deleterious.
TCGA somatic copy number variation data: we obtained arm-level and gene-level
CNV data from the PanCanAtlas Aneuploidy study (https://gdc.cancer.gov/about-data/
publications/pancanatlas, accessed date 11 August 2021) [15]. The acute myeloid leukemia
(LAML) data is not available, thus LAML was excluded from the CNV analysis. The
arm-level and gene-level events indicate that the copy number gain/loss effect an entire
chromosome arm or a specific genomic region that encodes gene. CNV was assessed
with Affymetrix SNP 6.0 arrays (Santa Clara, CA, USA) [15] and gene-level CNV values
were generated by GISTIC [14]. GISTIC calls of “−2” and “2” which indicate a loss or
gain of more than half of baseline ploidy were assigned as deep deletions or amplifica-
tion, respectively. Chromosome arm-level events were determined using the ABSOLUTE
algorithm [16]. Only deep deletions (−2) were considered for association analysis in
our study.
Hypermutators: we designated 344 TCGA cases hypermutated based on Bailey
et al. [21]. The hypermutators were defined as samples with mutation burden greater
than 1.5 times the interquartile range above the third quartile in their respective cancer
types, and the number of mutations in a sample exceeds 1000 [21].
MSI: as a measure of MSI, we took the MSIsensor scores which were derived from
standard tumor-normal paired sequence data from Niu et al. [22]. MSI cases were defined
as those with an MSIsensor score > 4 [22] according to the TCGA PanCanAtlas [21].
Genetic principal components of TCGA cohort: given that the ancestral genetic
background may influence genomic alterations, we obtain the pre-calculated principal
components (PCs) from the WashU genetic ancestry analysis of the TCGA PanCanAtlas
project [12,23]. The PCs were calculated on 298,004 variants with MAF > 0.15 and low
missingness, and PC1 and PC2 accounted for 51.6% and 29.2% of the variations across the
first 20 PCs [23] and were included as covariates in the regression analysis.
2.3. Association Analyses of Germline and Somatic Mutations Using Multivariate Regression
Models
We use a linear regression model to estimate the influence of germline or somatic
alterations on the HRD with the “glm” function of the “base” package of the R-project [24].
Since the HRD may be affected by age and genetic background, the analysis was controlled
for covariates, including patients’ age at diagnosis and population substructure (first two
PCs) [23]. The model is:
HRD ∼ Germline, somatic alteration (0, 1) + Age + PC1 + PC2
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Only genes with predisposing variants harbored at least 4 individuals within the
cancer cohort were included in the regression analysis. We perform this analysis within
each cancer type.
2.4. Association Analyses of Gene-Level CNV Using Multivariate Regression Models
We used a linear regression model to estimate the influence of gene-level CNV events
on the HRD with the “glm” function of the “base” package of the R-project. Given that the
copy number variation may be affected by age, gender, arm-level CNV, the analysis was
controlled for covariates, including patients’ age at diagnosis, gender, and arm-level CNV
events, as well as TMB and the first two PCs [15,23,25]. The model is:
HRD ∼ Gene-level CNV events (0, 1) + Age + Gender + TMB + Arm-level CNV events + PC1 + PC2
We performed this analysis within each cancer type. For breast cancer and prostate
cancer, we excluded gender from the covariates.
2.5. Independent Contribution of Germline and Somatic Mutations
We use a Partial Least Squares Path Modeling (PLS-PM) analysis to investigate the con-
tribution of germline and somatic mutations (Figure S3). The PLS-PM is a multivariate data
analysis method which introduces latent variables for analyzing systems of relationships
between multiple variables [26]. We include two latent variables (germline and somatic) in
our analysis. The PLS-PM algorithm includes measurement model and structural model.
The measurement model represents the relationships between the individual genes and the
latent variables which generates coefficient (β) denoting the contribution of mutant genes
to latent variable. The structural model represents the relationships between the latent
variables which also provides coefficient and p value measuring the relative contribution
of latent variables to HRD. In our analysis, we identified that germline and somatic muta-
tions of 30 DNA damage repair genes were associated with HRD. We only use the 9512
overlapped samples with germline, somatic, and signature data available in this analysis.
We perform PLS-PM analysis with the R packages “plspm” [27]. We compared the HRD
score in cases with germline, somatic, both germline and somatic HR mutations, and the
wildtype cases using the two-sided Mann–Whitney test.
2.6. Co-Occurrence and Mutual Exclusivity of Germline and Somatic Mutations
We estimate the interaction between germline predisposing variants and somatic
driver mutations by using Fisher’s exact test. We assign 0 if wild type and 1 if mutated to
each sample in the TCGA for each gene at both germline and somatic levels. We perform
this analysis across all samples and within each cancer types separately. We compared
the HRD score in cases with germline BRCA1, somatic TP53, both germline BRCA1 and
somatic TP53 mutations, and the wildtype cases using a two-sided Mann–Whitney test.
2.7. Adjustment for Multiple Comparisons
p values were adjusted by the Benjamini–Hochberg procedure for false discovery
rate (FDR) were computed globally across all analyses by genes and cancer types. All
the analyses in this study were performed using scripts written with the R programming
language. The significant effects of germline variants, somatic mutations, and somatic copy
number variations were defined as FDR < 0.05.
3. Results
3.1. Germline and Somatic Mutations Associated with HRD in 32 Cancer Types
We first examined if genomic alterations in 30 genes involved with HR are associated
with HRD phenotype captured by the HRD score of Knijnenburg et al. [13]. The HR genes
included 21 genes in the homologous recombination pathway and nine DNA damage
sensor-related genes (ATM, ATR, ATRIP, CHEK1, CHEK2, MDC1, RNMT, TOPBP1, TREX1)
(Table S2) [28–30]. We found that microsatellite instability (MSI) was correlated with HRD
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score in several cancer types (Figure S2). To mitigate potential noise caused by large
variations of genome instability in some cancers, we excluded hypermutators (n = 344) and
microsatellite instability (n = 226) tumors and limited subsequent analyses to the remaining
9512 cases, comprising 32 cancer types (Figure S1, Table S1). We found that 3.5% of the
9512 cases carried germline pathogenic variants (from now on referred to as germline
variants) and 4.5% harbored somatic driver mutations in HR genes. The percentages
of cases carried germline or somatic HR mutations varied across cancer types: ovarian
cancer (OV) showed the highest frequencies of germline variants (17.8%) and somatic
mutations (8.1%), followed by pancreatic cancer (PAAD), breast cancer (BRCA), stomach
cancer (STAD), and urothelial bladder carcinoma (BLCA) (Figure 1). These results illustrate
the distinct germline and somatic landscapes of HR mutations across cancer types.
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We next sought to identify the germline and somatic alterations that are associated
with the tumors’ HRD phenotype by using an HRD score, which was previously calculated
as a weighted sum of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI),
and Large-scale State Transitions (LST) events in tumor of the TCGA PanCanAtlas pr ject
across 32 cancer types [13].
Using a multivariate regression model, corrected for age and genetic ancestry represented
by principal components, we found 12 positive correlations between the HRD score and
germline variants in five (i.e., BRCA1, BRCA2, PABL2, ATM, ATR) genes across cancer types
(Table 1). Both, BRCA1 and BRCA2 variants were associated with higher HRD scores in BRCA
(FDR < 1.3 × 10−42) and OV (FDR < 5.0 × 10−12), BRCA2 (but not BRCA1) variants were
also associated with higher HRD of PAAD (FDR = 1.3 × 10−17) and stomach cancer (STAD)
(FDR = 6.7 × 10−17) (Table 1). We also found that germline PALB2 variants are associated
with higher HRD in STAD (FDR = 1.2 × 10−41). Germline ATR and ATM were associated
with higher HRD in BRCA (FDR < 8.5 × 10−8), and germline ATM variants in prostate cancer
(PRAD, FDR = 9.0 × 10−6), lung adenocarcinoma (LUAD, FDR = 5.8 × 10−5), and STAD
(FDR = 0.007) (Table 1). While BRCA1/2 germline variants in BRCA, OV, PAAD and prostate
cancer are well known to be associated with HRD phenotype, our results identify a much
broader range of cancers with different germline alterations in HR-related genes that are
significantly associated with HRD (Tables 1 and S3).
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Table 1. The significant associations (FDR < 0.05) of germline variants and somatic mutations with HRD phenotype.
Index Cancer Gene Mutation Type Number of Cases Affected (%) Correlation Coefficients FDR
1 BRCA BRCA1 germline 18 (1.8) 0.91 <1.0 × 10−50
2 BRCA BRCA2 germline 16 (1.6) 0.63 <1.0 × 10−50
3 OV BRCA1 germline 35 (9.1) 0.32 1.3 × 10−42
4 STAD PALB2 germline 4 (1.1) 0.84 1.2 × 10−41
5 PAAD BRCA2 germline 5 (3) 0.70 1.3 × 10−17
6 STAD BRCA2 germline 4 (1.1) 0.61 6.7 × 10−17
7 OV BRCA2 germline 26 (6.8) 0.20 5.0 × 10−12
8 BRCA ATR germline 5 (0.5) 0.47 7.7 × 10−12
9 BRCA ATM germline 9 (0.9) 0.32 8.5 × 10−8
10 PRAD ATM germline 6 (1.2) 0.45 9.0 × 10−6
11 LUAD ATM germline 6 (1.2) 0.30 5.8 × 10−5
12 STAD ATM germline 6 (1.7) 0.25 0.007
13 BRCA BRCA1 somatic 15 (1.5) 0.79 <1.0 × 10−50
14 BRCA BRCA2 somatic 11 (1.1) 0.81 <1.0 × 10−50
15 BLCA BRCA2 somatic 7 (1.8) 0.56 1.6 × 10−21
16 OV BRCA1 somatic 17 (4.4) 0.27 5.1 × 10−17
17 UCEC ATM somatic 15 (4.4) −0.70 2.9 × 10−13
18 LUSC BRCA2 somatic 7 (1.5) 0.35 6.4 × 10−10
19 BLCA BRCA1 somatic 6 (1.5) 0.37 1.5 × 10−8
20 STAD BRCA2 somatic 4 (1.1) 0.44 1.5 × 10−8
21 UCEC BRCA2 somatic 7 (2) −0.80 1.5 × 10−8
22 BLCA ATM somatic 23 (5.9) 0.20 1.7 × 10−7
23 UCEC CHEK2 somatic 4 (1.2) 0.51 3.3 × 10−7
24 LUAD ATM somatic 24 (4.9) 0.18 1.3 × 10−5
25 OV BRCA2 somatic 7 (1.8) 0.23 2.2 × 10−5
26 PRAD BRCA2 somatic 5 (1) 0.42 7.8 × 10−5
27 CRC ATM somatic 23 (5.2) 0.20 0.0003
28 PRAD ATM somatic 15 (3) 0.24 0.0007
29 LUSC BRCA1 somatic 6 (1.3) 0.21 0.002
30 LUAD BRCA2 somatic 4 (0.8) −0.46 0.004
31 HNSC ATR somatic 4 (0.8) 0.27 0.005
32 BRCA ATM somatic 14 (1.4) 0.14 0.007
33 KIRC ATR somatic 4 (1.1) 0.47 0.008
34 CRC BRCA2 somatic 6 (1.4) 0.27 0.01
35 SKCM BRCA2 somatic 4 (0.9) −0.39 0.02
36 LUSC ATR somatic 4 (0.9) −0.22 0.03
CHOL: Cholangiocarcinoma; ACC: Adrenocortical carcinoma; BLCA: Bladder Urothelial Carcinoma; BRCA: Breast invasive carcinoma;
CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; COADREAD: Colon Rectum adenocarcinoma; DLBC:
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC: Head and
Neck squamous cell carcinoma; KICH: Kidney Chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary
cell carcinoma; LAML: Acute Myeloid Leukemia; LGG: Brain Lower Grade Glioma; LIHC: Liver hepatocellular carcinoma; LUAD:
Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; OV: Ovarian serous cystadenocarcinoma; PAAD:
Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and Paraganglioma; PRAD: Prostate adenocarcinoma; SARC: Sarcoma; SKCM:
Skin Cutaneous Melanoma; STAD: Stomach adenocarcinoma; TGCT: Testicular Germ Cell Tumors; THCA: Thyroid carcinoma; THYM:
Thymoma; UCEC: Uterine Corpus Endometrial Carcinoma; UCS: Uterine Carcinosarcoma; UVM: Uveal Melanoma.
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We conducted a similar multivariate regression analysis for somatic mutations, and
identified 24 significant associations in five (i.e., BRCA1, BRCA2, ATM, ATR, CHEK2) genes
and higher HRD (FDR < 0.05) across cancer types. Somatic mutations of BRCA1 and BRCA2
were significantly associated with HRD in BRCA, OV, and BLCA, and lung squamous cell
carcinoma (LUSC) (FDR < 0.002, Table 1). Somatic BRCA2 mutations were also associated
with HRD in STAD, PRAD, and colon rectum adenocarcinoma (CRC) (FDR < 0.01). Somatic
mutations of ATM and ATR were associated with higher HRD in BLCA, LUAD, CRC,
PRAD, head–neck squamous cell carcinoma (HNSC), BRCA, and kidney renal clear cell
carcinoma (KIRC) (FDR < 0.008, Table 1). Somatic mutations of CHEK2 significantly
increased HRD in uterine corpus endometrial carcinoma (UCEC, FDR < 3.3×10−7, Table 1).
Of note, we also identified negative associations between HRD scores and somatic HR
mutations in cancer types including UCEC, LUAD, skin cutaneous melanoma (SKCM),
and LUSC (FDR < 0.03, Table 1). Overall, these results highlight that both germline and
somatic mutations can be associated with high HRD and the importance of different HR
genes to maintain genomic stability can vary from cancer type to cancer type.
3.2. Relative Contributions of Germline and Somatic Mutations on HRD
To delineate the relative contributions of germline variants vs. somatic mutations to
the tumor HRD phenotype, we applied Partial Least Squares Path Modeling (PLS-PM) [26].
In this analysis, we only considered genes that were affected in at least four TCGA cases
within a cancer type and therefore only seven genes (BRCA1/2, ATM, ATR, PALB2, CHEK2,
BRIP1) were included. This may neglect the contribution of other HR genes with lower
mutation frequencies, but we have limited power to identify these in the current data
set. Both germline and somatic mutations significantly contributed to the HRD of BRCA
(FDR < 1.5 × 10−12) and OV (FDR < 2.4 × 10−4, (Figure 2A)). In STAD and PAAD, mostly
germline variants contributed to high HRD (FDR < 7.2 × 10−4), whereas in BLCA and
LUSC high HRD were “driven” mainly by somatic mutations (FDR < 0.01, (Figure 2A)). We
show the distribution of HRD scores in these cancer types by mutation status on Figure 2B.
The PLS-PM analysis also allows to quantify the relative contribution of individual
gene’s to predicting higher HRD when combining all the contributors together. Both
germline variants and somatic mutations of BRCA1/2 (β > 0.32) dominantly contributed
to HRD in BRCA and OV, while only germline BRCA2 contributed to HRD in PAAD
(Figure 2C). Germline PALB2 (β = 0.79) and BRCA2 (β = 0.46) and ATM (β = 0.36) variants
contributed to HRD of STAD, with non-significant effects from somatic BRCA2 (β = 0.97)
and ATM (β = 0.21) (Figure 2C). On the other hand, somatic BRCA1 (β = 0.52), BRCA2
(β = 0.65) and ATM (β = 0.59) contributed to HRD in BLCA (Figure 2C). These results
highlight that somatic and germline alterations in specific HR genes contribute differently
to HRD in different cancer types.
3.3. Germline-Somatic Interactions Shaping HRD
Germline variants and somatic mutations can complement each other in the malig-
nant transformation process [12,31,32], and together they can shape tumor phenotypes
including HRD. To identify germline–somatic mutation pairs that may cooperate to affect
HRD, we first identified the significant co-occurring germline–somatic mutation pairs con-
sidering germline variants in the 30 HR genes vs. the PanCanAtlas-defined somatic driver
genes (n = 299) across all TCGA cancer cases and also within each cancer types using the
Fisher’s exact test. Germline BRCA1 mutations significantly co-occurred with somatic TP53
mutations at both the pan-cancer level (FDR = 1.0 × 10−6, Figure 3A) and within breast
cancer (FDR = 6.2 × 10−4, Figure 3B). We also detected trends of other germline-somatic
co-occurrences, including mutually exclusive alterations between germline BRCA1/2 and
somatic PIK3CA (FDR = 0.2, p = 0.001), we found no other germline–somatic pairs that
reached significance. In BRCA, samples that carried both germline BRCA1 and somatic
TP53 mutations had higher HRD scores compared to cases with only germline BRCA1
alteration (p = 0.08), or with somatic TP53 mutation only (p = 2.9 × 10−6), or cases that
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were wild type for both (p = 6.4 × 10−11) (Figure 3C). These results demonstrate that
while germline and somatic mutations may induce independent effects, tumors carrying
both pathogenic BRCA1 germline variants and TP53 driver mutations show markedly
increased HRD.
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Figure 2. The combined contributions of germline variants and somatic mutations to HRD. (A). The combined germline
and somatic contributions represented by coefficients obtained from the PLS-PM analysis. Each dot represents a cancer
type. The size of the circles represents −log10(p). Grey, purple, blue, and red represent none of, somatic, germline, or
both FDR meet the c iteria FDR < 0.05. The grey line indicates the diagonal with sl p of one. (B). The distribution of
HRD score in combined germline nd somatic carriers in BRCA (n = (both), 53 (germline), 38 (somatic), 850 (wildtype)),
OV (n = 66 (germline), 31 (somatic), 272 (wildtype)), PAAD (n = 12 (germline), 8 (somatic), 131 (wildtype)), STAD (n = 18
(germline), 15 (somatic), 309 (wildtype)), BLCA (n = 5 (both), 10 (germline), 32 (somatic), 334 (wildtype)). p-value was
calculated using a two-sided Mann–Whitney test and FDR corrected. “***”, “**”, “*” denote FDR less than 0.0001, 0.001,
and 0.05. (C). PLS-PM models show the significant combined contribution of germline variants and somatic mutations
with FDR < 0.05 of combined effect in selected cancer types, including BRCA, OV, PAAD, STAD, and BLCA. The numbers
between the latent variables and HRD indicated combined correlation coefficients identified by the PM-PLS model, the
value. “****”, “***”, “**”, denote FDR less than 0.00001, 0.0001, and 0.001. “n.s.” denotes “not significant” (FDR > 0.05).
3.4. Somatic Copy Number Variations Associated with HRD
Somatic copy number deletion of genes involved in HR may also compromise HR.
Given that the calculation of HRD scores included copy number variation of BRCA1/2
genes, we assessed the associations between HRD and copy number deletions focusing
only on the rest of 28 HR genes. Overall, 7.0% of the non-hypermutator/microsatellite
stable cases had somatic copy number deletions of genes involved in HR, excluding BRCA1
and BRCA2. Across cancer types, diffuse large B-cell lymphoma (DLBC) had the highest
frequency of deletions (24.3%) in the HR genes, followed by PRAD (11.5%), and testicular
germ cell tumors (TGCT) (11.7%) (Figure 4A). About 5.6% of BRCA and 7.6% of OV cases
were affected by HR gene deletions (excluding BRCA1/2) (Figure 4A).
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Figure 4. Somatic copy number deletions of HR genes associated with HRD. (A). The proportions of samples with somatic
copy number deletion of homologous recombination and damage sensor genes in each cancer type. Blue (loss) indicates
samples with somatic copy number deletions in any of 28 HR genes (excluding BRCA1/2), grey (WT) denotes non-mutated
cases. (B). The HRD score between cases with somatic copy number deletion (DEL) of homologous recombination and
damage sensor genes and wildtype (WT) cases excluding BRCA1/2 copy number variation affected cases in OV (n = 28
(DEL), 332 (WT)), BRCA (n = 53 (DEL), 860 (WT)), SARC (n = 23 (DEL), 193 (WT)), TGCT (n = 15 (DEL), 113 (WT)), ACC
(n = 7 (DEL), 74 (WT)), UCEC (n = 16 (DEL), 303 (WT)). p-value was calculated using a two-sided Mann–Whitney test and
FDR corrected. “****”, “**”, “*” denote FDR less than 0.00001, 0.001, and 0.05. (C). The heatmap shows the significant (FDR
< 0.05, black box) association of somatic copy number deletion of individual genes with the HRD of TCGA cancer types.
Both value and color in each cell represent the coefficient obtained from the multivariate logistic regression model.
Cases with at least one somatic copy-number deletion in any of the HR genes (exclud-
ing BRCA1/2) showed significantly higher HRD scores compare to cases without deletions
in OV, BRCA, Sarcoma (SARC), TGCT, adrenocortical carcinoma (ACC), low grade glioma
(LGG), and UCEC (FDR < 0.05) (Figure 4B). Applying a multivariate regression model,
we further compared the HRD scores between copy number deletion vs. wildtype cases
at the gene level. Deletions of ATM, RAD51, MRE11A, CHEK1, and BARD1 were associ-
ated with higher HRD of BRCA. We also identified other deletions associated with higher
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HRD in multiple cancer types, such as XRCC2/3 and BARD1 deletion in BLCA, TP53BP1,
and RAD51 deletion in OV and LUAD, and CHEK1 deletion in TCGT and SKCM, etc.
(Figure 4C). These analyses show that not only mutations but copy number deletions
in HR genes can also be associated with HRD and might confer sensitivity to PARPi,
warranting further mechanistic and clinical investigations.
4. Discussion
This study comprehensively evaluated the associations between deleterious germline
variants, somatic driver mutations, and somatic copy number deletions in 30 HR-related
genes and the HRD phenotype of 32 cancer types. We demonstrated that aside from
BRCA1/2 in well-known BRCA-associated cancer types (breast, ovarian, pancreatic, and
prostate), several other HR gene mutations are associated with HRD in a broad range of
cancers. Both germline variants and somatic mutations of HR genes can be associated with
HRD phenotype. Further, their individual contributions (i.e., strength of association) and
synergistic interactions between them varied by cancer type. We also demonstrated that
somatic copy number deletions of HR genes are associated with HRD. These results expand
the repertoire of genes and type of genomic abnormalities that may cause HRD. Further
clinical studies could further validate whether these alterations could serve as potential
biomarkers for treatments exploiting synthetic lethality to treat tumors with impaired HR
in a broader range of cancer types.
Several PARPi have already been approved for clinical use. The US FDA approved
olaparib for the treatment of germline BRCA-mutated breast, prostate, ovarian, and pancre-
atic cancer patients; talazoparib is also approved for germline BRCA mutated breast and
ovarian cancers [33,34]. The NOVA study demonstrated that niraparib improved survival
of somatic BRCA1/2 mutant or BRCA normal but HRD positive by the Myriad myChoice
CDx assay ovarian cancer [4]. The TBCRC-048 trial, demonstrated the efficacy of Olaparib
in somatic BRCA mutant and germline PALB2 mutant metastatic breast cancers [7]. Con-
sistent with these clinical observations, our results demonstrate that either germline or
somatic mutations in BRCA1/2 genes can be associated with HRD phenotype of breast and
ovarian cancer. In addition to the known associations, our data also suggests that there
could be additional subsets of patients who might benefit from HR targeted therapies. For
example, germline PALB2 variants have recently been associated with familial and sporadic
stomach cancer [35]. We found that germline PALB2 variants were positively correlated
with HRD in stomach cancers. Deleterious germline variants in ATR and ATM were also
associated with HRD phenotype in breast cancer, ATM in prostate, lung, and stomach
cancers, and BRCA2 in stomach cancers.
Somatic mutations of BRCA1/2 were also significantly associated with HRD in breast
and ovarian cancers and these associations are already clinically exploited. Notably, BRCA2
mutations were also associated with HRD in urothelial, squamous cell lung, and stomach
carcinomas, where tumor response to PARPi has not yet been associated with HR mutations
or HRD. We also identified previously unreported associations of somatic mutations of
several other HR genes with HRD phenotype, suggesting new patient subsets that may
benefit from PARPi. For example, somatic BRCA2 and ATM mutations were correlated
with HRD in bladder cancer, lung cancer, and colon cancer. Moreover, ATR mutations were
associated with high HRD scores in head and neck cancer and kidney cancer (Table 1).
We also noted that germline and somatic mutations contribute differently to the HRD
phenotype in different cancer types. Both germline and somatic mutations significantly
contributed almost equally to HRD in breast cancer. In stomach and prostate cancers, HRD
was predominantly influenced by germline variants, whereas in bladder cancer somatic
mutations contributed to the majority of tumors with HRD phenotype.
The effects of copy number variants on HRD and PARPi response have rarely been
investigated, and only a few studies have reported ATM, BRCA1, and BRCA2 deletions
could affect sensitivity to DNA damaging chemotherapies [36–38]. In our analysis, we
found that somatic copy number deletions in several HR genes, such as ATM, RAD51,
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and CHEK1 were associated with increased HRD phenotype in OV, BRCA, SARC, and
TGCT. The results suggest that somatic copy number deletion of HR genes should also be
evaluated as potential biomarkers for predicting HRD and PARPi sensitivity.
One limitation of the study is that the identified associations do not imply causality,
and require further experimental validation. We also recognize that results from a clinically
used HRD test is not available for any of the TCGA cases. Our HRD scores were derived
from the SNP array and WES data that resemble the myChoice® CDx HRD assay according
to the TCGA Pan-Cancer Atlas project. The HRD scores used in this study may limit
the detection of HRD tumors. Further, observing an HRD phenotype may not guarantee
PARPi sensitivity in tumors. Future studies using clinical cohorts with genomic and PARPi
response data are needed to validate whether these tumors may be effectively treated by
therapies exploiting synthetic lethality.
5. Conclusions
Our results showed that the HRD phenotype is associated with several genomic
alterations in genes involved with homologous recombination across both BRCA-associated
and non-BRCA-associated cancer types. These findings raise the possibility that many
subpopulations of cancer patients might benefit from PARP inhibitors and other HR-
targeted therapies.
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